Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2008

View Archived Issues

AstraZeneca reports full year 2007 R&D highlights

GeoVax Clade B DNA/MVA HIV/AIDS vaccine to proceed to phase II

VICTOR-E1 data show sustained viral suppression with vicriviroc in HIV patients

FDA grants approval to Diamyd to initiate phase I trial of NP-2 for chronic pain

Raltegravir efficacy maintained through 48 weeks in BENCHMRK studies

Icagen announces completion of investment by Pfizer

NRDL and Lilly sign drug development agreement spanning multiple therapeutic areas

AnGes reports results from phase II clinical trials of ointment for atopic dermatitis

New therapeutic agents for cardiovascular disorders reported in recent patent literature

Novel immunomodulators disclosed in recent patents

Low-dose arm continues to be tested in phase III MDP 301 trial of Indevus' PRO-2000

EMEA recommends that new warnings be included in product information for Novartis' Sebivo

Can-Fite doses first cohort of patients in phase I CF-102 trial

FDA grants fast track status to levodopa/carbidopa intestinal gel

LAT-967 shows potential for AD by inducing Sp1 degradation

Takeda discontinues matuzumab development

Agonist-induced CCR5 internalization, an alternative mechanism to prevent HIV infection

Lundbeck initiates enrollment in phase II clinical study of Lu-AA-34893 for bipolar disorder

Recent patents describe novel compounds for the treatment of cancer

Activation of osteoblast GPCRs potentially useful as bone repair therapy

FDA approves Xyzal oral solution for the relief of allergies and urticaria

Newron completes enrollment in phase II study of ralfinamide in post-op dental pain

Bayer and Onyx terminate clinical phase III Nexavar study in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.